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A B S T R A C T

Continuous femoral nerve block (CFNB) has been used to prevent the breakthrough pain after total knee
arthroplasty (TKA). Multimodal drug injection (PMDI) has also been shown to decrease opioid
consumption and pain. We investigated whether the use of PMDI further improves analgesic and
rehabilitation outcomes when used in conjunction with CFNB. This is a prospective randomized
controlled study of 44 patients undergoing primary TKA. The treatment group (n = 23) received a PMDI of
combined ropivacaine, epinephrine, ketorolac and morphine, and the controlled group (n = 21) received
saline at wound closure. Total opioid consumption, pain scores, knee range of motion (ROM) outcomes,
length of stay, and patient satisfaction were measured and compared. The total consumption of morphine
is similar between the two groups (52.6  40.6 vs. 41.5  32.9, p = 0.325). The mean morphine
consumption of the treatment group was signiﬁcantly lower than the control at 4 h after surgery
(4.2  5.5 vs. 11.3  8.1, p = 0.002) but comparable on POD1, POD2, and POD3. The mean pain scores were
signiﬁcantly higher in the treatment group than the control group at POD2 (at rest: 47.3  29.1 vs.
23.8  20.6, p = 0.004; after PT: 57.7  25.4 vs. 35.2  26.8, p = 0.007) and POD3 (at rest: 30.9  30.3 vs.
14.8  20.9, p = 0.045; after PT: 50.2  30.6 vs. 29.0  32.1, p = 0.035), and not signiﬁcantly different at 4 h
after surgery or at POD1. Mean maximal knee ﬂexion ROM in degrees during active and active assisted
mobilization showed no signiﬁcant difference between the control and the treatment groups on POD2
and POD3. The mean length of stay of the treatment group is signiﬁcantly longer than the control group
(5.1  2.1 vs. 3.8  1.6, p = 0.032). At discharge, no signiﬁcant difference exists between the two groups for
mean patient satisfaction. The addition of PMDI led to a decrease in opioid consumption in the immediate
postoperative period but with no signiﬁcant difference in the total consumption within the ﬁrst three
days postoperatively. This ﬁnding provides an opportunity for appropriate preoperative treatment and
education for both patients and caregivers.
© 2017
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1. Introduction
Effective pain management is crucial for successful outcomes
and patient satisfaction following total knee arthroplasty (TKA).1,2
Proper analgesia can not only facilitate early rehabilitation and
reduce hospital length of stay, but can even result in decreased
healthcare costs.3 The administration of parenteral opioids
including patient controlled analgesia (IVPCA) have been historically utilized as the mainstay treatment for acute postoperative
pain. However, opioids may not always provide adequate pain
relief, and are commonly associated with undesirable side effects,
such as sedation, nausea, vomiting, ileus, urinary retention,
hypotension, pruritus, and respiratory depression.4–6 In order to
maximize the analgesia and to minimize the side effects, a
multimodal approach with preemptive analgesia has become
popular, and includes a combination of peripheral nerve blocks,
epidural catheters, non-steroidal anti-inﬂammatory drugs
(NSAIDs), oral narcotics, and periarticular multimodal drug
injection (PMDI).7–10
Continuous femoral nerve blocks (CFNB) are known to improve
analgesia after TKA when used in conjunction with a multimodal
approach.11–13 However, some patients may still experience
breakthrough pain, possibly due to the fact that the obturator
and sciatic nerve distributions are not blocked. Similarly, a PMDI of
ropivacaine, ketorolac and morphine has shown to decrease opioid
consumption and postoperative pain after TKA.14–16 This drug
combination has been shown to be synergistic; and the addition of
epinephrine has shown to reduce the potential toxicity of the
ropivacaine by reducing its systemic distribution.7 Both CFNB and
PMDI have been shown to improve pain independently after a
primary TKA.17 We hypothesized that a combination of PMDI and a
CFNB further reduced opioid consumption and postoperative pain
in patients undergoing TKA. In addition, we attempted to
determine if patients with this pain control regimen experience

Table 1
Total joints protocol.
Pre-op (holding area) meds
Coumadin 5 mg PO  1 dose (ONLY in select pts)
Protonix 40 mg PO  1dose
Oxycontin 10 mg PO  1dose (avoid in elderly and pts with sleep apnoea)
Celebrex 200 mg po  1 dose (not for sulphur allergic pts) (not available at County)
Gabapentin 300 mg
Anesthesia
Spinal with bupivacaine 0.5% 12–15 mg to attain a standard T10 level block
Intra-op Cocktail
Treatment group
Ropivacaine 400 mg
Epinephrine diluted 1:1000 in saline (0.6 mL)
Ketorolac 30 mg
Morphine sulfate 5 mg
*** Diluted to a total volume of 100 mL with normal saline
Control group
100 mL normal saline
Continuous femoral nerve block
Ropivacaine 0.2% infused at 5 mL/h
Orthopedic Floor
Celecoxib 200 mg orally, daily for 10 days ((not for sulphur allergic pts)
Acetaminophen 650–1000 mg orally q 4–6 h (total dose of not to exceed 4 gm/day)
Gabapentin 300 mg (caution in renal disease and delirious pts)
Ketorolac IM q 6 h PRN
15 mg if more than 65 years, 30 mg if less than 65 years;
Hold if renal impairement, GI bleeding or other contraindication
Not more than 3 days
If ketorolac is ineffective, morphine 2–4 mg IM q 2–4 h prn for pain

better early rehabilitations, early discharge and have less opioid
related side effects than those who did not.
2. Materials and methods
After obtaining approval by our Institutional Review Board
(IRB), we conducted a single center, prospective, placebocontrolled, double blind trial to assess the efﬁcacy of PMDI of a
multi-drug regimen in addition to a CFNB in alleviating pain after
TKA when used in conjunction with an established multimodal
regimen (Table 1). All patients scheduled for elective unilateral
primary TKA for a primary osteoarthritis between the years April
2009-July 2013 at an academic teaching hospital were considered
for this study. Patient exclusion criteria included: (1) age younger
than 18 years, (2) weight exceeding 120 kg, (3) inability to
understand pain scales or the use of the IVPCA device, (4) history
of chronic opioid consumption, (5) opioid use in last 6 weeks
before surgery, (6) chronic pain syndromes, (7) allergy to local
anesthetics and/or opioids, (8) previous lower extremity vascular
surgery, (9) peripheral neuropathy, (10) diagnosis other than
primary osteoarthritis, and (11) unwilling to participate in the
study.
Using a computer-generated list of random numbers, patients
were randomized and blinded to receive either a PMDI mixture
(treatment group) (Table 1) or a placebo periarticular injection
containing 100 mL of normal saline (control group). All patients
included in this study received a spinal anesthesia of 12–15 mg of
bupivacaine 0.5% to attain a standard T6-T8 level block for the
surgery. These surgeries proceeded with a standard medial
parapatellar approach under tourniquet and a drain was placed
before wound closure. In the treatment group, PMDI containing
ropivacaine 400 mg, epinephrine diluted 1:1000 in saline (0.6 mL),
ketorolac 30 mg and 5 mg of morphine were diluted to a total
volume of 100 mL with normal saline was inﬁltrated around the
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knee joint into the posterior aspect of the capsule, medial and
lateral collateral ligaments and gutters, and the subcuticular
tissues.
Postoperatively, all patients had access to postoperative IVPCA
for breakthrough pain in addition to the standard multiple modal
pain regimen before and after the procedure (Table 1). In the postanesthesia care unit (PACU), when the patients show some return
of motor function, a CFNB was placed for all subjects. A femoral
nerve catheter was introduced by the same anesthesiologist under
ultrasound guidance. The femoral artery was visualized and the
quadriceps contractions were obtained via a neurostimulator.
Femoral nerve was also located in an out-of-plane approach.
Following negative aspiration, approximately 15 mL of 0.5%
ropivacaine was injected. Ultrasound conﬁrmed the dispersion
of the solution around the nerve bundle. A catheter was inserted
beyond the tip of the needle without resistance then a continuous
infusion ﬁlled with ropivacaine 0.2% at 5 mL/h was started via an
elastomeric pump. A morphine IVPCA consisting of a non-basal
infusion of morphine sulfate (1 mg) every 6 min with 10 mg
maximum per hour, was initiated in the PACU and continued until
postoperative day 3. Thereafter, patients were transitioned to oral
pain medications.
Patient parameters such as gender, age, BMI and ASA score were
collected for comparison. Postoperative outcome data were
collected by a pain nurse practitioner who was blinded to the
randomization assignments. Primary outcome variables collected
were opioid consumption and pain scores. Daily opioid consumption was recorded in terms of milligram total morphine used via
intravenous PCA. A visual analog scale (VAS) with scores ranging
from 0 to 100 was used to capture the pain score at rest four hours
after surgery. In addition, pain scores at rest and after physical
therapy (PT) on postoperative day (POD) 1, POD 2, and POD 3 were
also obtained.
Mobilization was encouraged on the day of surgery and formal
PT with weight bearing as tolerated was started on the morning of
postoperative day 1 with two sessions each day of hospital stay.
Secondary outcome variables included active (self initiated) and
active assisted (PT assisted) knee ROM (measured in degrees) on
POD 2 and POD 3, medication side effects, length of stay, and
patient satisfaction. From POD 1 until discharge, patients
performed daily knee ﬂexion and extension exercises. The degree
of active and active assisted ROM achieved by the patients was
measured by a physical therapist starting POD 2. Side effects from
any of the medications and pain modalities, including nausea,
vomiting, dizziness, drowsiness, confusion, pruritus, constipation,
hypotension, urinary retention, respiratory depression, and fall,
were also documented. Patient satisfaction was assessed using a
simple satisfaction survey questionnaire administered just before
discharge. Patients were asked to quantify their degree of
satisfaction using a scale from 0 to 10.
Analysis was done with the aid of a statistical software (IBM,
SPSS Version 22, New York, NY). A power analysis was performed
based on estimates used in a previous study by Adam et al.,11 which
revealed that 20 patients were needed per group, with a maximum
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a beta-error of 20%, for detecting a 40% difference in morphine
consumption at a signiﬁcance level of 0.05. Descriptive statistical
analysis with means and their standard deviation values for
measurements at each time point were calculated. Data were
analyzed to test the differences in primary measures between the
control and the experimental groups using either a Student’s
unpaired 2-tailed t-tests or a contingent Mann-Whitney U test on
the scale and distributional characteristics of the variables using a
p value of less than 0.05 to consider the differences between the
cohorts as statistically signiﬁcant.
3. Results
Forty-four patients enrolled in this study and were allocated
into treatment group (n = 23) and control group (n = 21). Demographic characteristics between the two groups were comparable
in terms of age (64.76  8.35 control vs. 62.39  11.39 experimental), and BMI (32.83  5.47 control vs. 33.12  5.52 experimental).
There are 85.7% females (n = 18) in the control group and 73.9%
females in the experimental group (n = 17). The ASA scores for
patients from both groups range from II–III with 42.9% (n = 9) of the
control and 56.5% (n = 13) of the experimental with ASA score of II,
and 57.1% (n = 12) of the control and 43.5% (n = 10) of the
experimental with ASA score of III (Table 2).
The total consumption of morphine is similar between the two
groups (52.6  40.6 vs. 41.5  32.9, p = 0.325). By time period, the
mean morphine consumption of the treatment group was
signiﬁcantly lower than the control at 4 h after surgery
(4.2  5.5 vs. 11.3  8.1, p = 0.002) but similar on POD1
(14.4  15.0 vs. 23.6  20.4, p = 0.100), POD2 (19.9  17 vs.
15.5  13.6, p = 0.348) and POD3 (2.9  6.4 vs. 2.2  4.1, p = 0.653)
(Fig. 1). The mean VAS scores were signiﬁcantly higher in the
treatment group vs the control group at POD2 (at rest: 47.3  29.1
vs. 23.8  20.6, p = 0.004; after PT: 57.7  25.4 vs. 35.2  26.8,
p = 0.007) and POD3 (at rest: 30.9  30.3 vs. 14.8  20.9, p = 0.045;
after PT: 50.2  30.6 vs. 29.0  32.1, p = 0.035), and not signiﬁcantly
different at 4 h after surgery (14.3  17.0 vs. 24.5  28.9, p = 0.169)
or at POD1 at rest and after PT (at rest: 37.6  35.3 vs. 35.2  27.9,
p = 0.805; after PT: 50.2  34.8 vs. 54.2  26.7, p = 0.676) (Fig. 2a and
b). A standard mixture of PMDI was used in all patients in the
treatment group, weight adjusted doses did not show a signiﬁcant
correlation with morphine consumption (r = 0.074, p = 0.570 for all
agents, ropivacaine, epinephrine, ketorolac, and morphine sulfate).
Mean maximal knee ﬂexion ROM in degrees during active and
passive knee mobilization were measured on POD2 and POD3 and

Table 2
Demographic information of control and experimental groups.

Age (yr)
BMI
Males%(n)
Females%(n)
ASA II%(n)
ASA III%(n)

Control
(n = 21)

Experimental
(n = 23)

64.76  8.35
32.83  5.47
14.3(3)
85.7(18)
42.9(9)
57.1(12)

62.39  11.39
33.12  5.52
26.1(6)
73.9(17)
56.5(13)
43.5(10)

Fig. 1. Mean morphine patient-controlled analgesia (PCA) consumption at
sequential times after surgery for control and experimental groups. The bars
depict mean values for experimental and control groups, with whiskers
representing standard error values. The mean PCA consumption of the treatment
group was signiﬁcantly lower than the control at 4 h after surgery (p = 0.002) but not
signiﬁcantly lower on POD1 (p = 0.100), POD2 (0.348) and POD3 (0.653).
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showed no signiﬁcant difference between the control and the
treatment groups for all conditions on POD2 (active: 33.1 16.3 vs.
38.7  17.5, p = 0.320; assisted active: 62.0  13.8 vs. 52.7  17.5,
p = 0.084) and POD3 (active: 46.5  20.4 vs. 45.4  16.7, p = 0.864;
assisted active: 69.7  16.8 vs. 60.4  15.6, p = 0.107) (Fig. 3).
There was no signiﬁcant difference in the opioid side effects’
proﬁles between the two groups at 4 h after surgery (8.7% vs. 9.52%,
p = 0.904), POD1 (34.78% vs. 42.86%, p = 0.779), POD2 (21.74% vs.
14.28%, p = 0.522), and POD3 (52.17% vs. 47.62%, p = 0.764). Side
effects experienced by the two groups include constipation,
confusion, dizziness, drowsiness, nausea, pruritus, and pruritus.
No adverse effect of the PMDI or CFNB such as falls was seen in this
study (Table 3). The mean length of stay of the treatment group is
signiﬁcantly longer than the control group (5.1  2.1 vs. 3.8  1.6,
p = 0.032) with large percentage of control group being charged by
POD3 (66.7% vs. 43.4%, p = 0.124). At discharge, no signiﬁcant
difference exist between the two groups for mean satisfaction
scores, control M (SD) = 8.3(1.8), treatment M (SD) = 9.0(1.2).
4. Discussion
Effective analgesia facilitates early rehabilitation, reduces
hospital length of stay, and decreases overall healthcare costs.3
Opioids have been a historical mainstay in perioperative analgesia
but have a wide range of undesirable side effects that can affect
rehabilitation.4–6 Periarticular multimodal drug injection, continuous femoral nerve blocks, as well as other multimodal regimens
improve analgesia while avoiding the side effects of opioids.7,8,11–13
There has been comparisons of single shot FNB with single shot
PMDI, and continuous PMDI to continuous FNB,14 but there is a lack
of evidence speciﬁcally comparing continuous FNB with and
without PMDI. PMDI with FNB in TKA leads to a decrease in opioid

Fig. 2. a&b Mean pain scores for control and experimental groups before and after
physical therapy (PT) using a visual analog scale (VAS) from 0 to 100. Bars depict
mean values for experimental and control groups, with whiskers representing
standard error values. Before PT (Fig. 2a), the mean pain score was signiﬁcantly
higher in the treatment group at POD2 (p = 0.004) and POD3 (p = 0.045). After PT
(Fig. 2b), the mean pain score was signiﬁcantly higher for the treatment group at
POD2 (p = 0.007) and POD3 (p = 0.035).

consumption within the ﬁrst four hours after surgery. However, the
difference in the total morphine consumption over the ﬁrst three
days postoperatively is not statistically signiﬁcant.
This study had several limitations. A single standard dose of
ropivacaine was used instead of weight-adjusted dose. This was
standardized between our two cohorts, but toxic plasma levels
were not reached despite high concentration injection as
demonstrated in previous studies.18,19 Second, the residual effects
of intraoperative spinal anesthesia, which could vary in different
patients, may have confounded the pain score and opioid
consumption outcomes during the ﬁrst 4 h of the postoperative
period, but this was same for both groups. Although the study was
statistically powered, the number of patients enrolled was
relatively smaller with a relatively larger dropout in our setting.
The pain and satisfaction scores are often subjective and
dependent on individual patient characteristics, and thus are
unavoidable sources of bias in any pain management study.
Although there are several other options in a multimodal approach,
we have only compared the addition of PMDI option to a
continuous FNB, and thus this study does not identify the best
available option for analgesia after a primary TKA. Despite these
limitations, in an adequately powered randomized doubly blinded
study, we were able to show that the total consumption of opiate
did not differ signiﬁcantly between the treatment and the control
groups.
The current literature is saturated with studies analyzing PMDI
and other multimodal regimens. Busch et al.15 compared the use of
a PMDI mixture 400 mg of ropivacaine, 30 mg Ketorolac, 5 mg of
epimorphine, and 0.6 mL of Epinephrine (1:1000) intraoperative
injection with no injections and showed injections signiﬁcantly
reduced patient-controlled analgesia with decreased VAS for pain
and increased VAS for satisfaction during ﬁrst 24 h; however, their
evaluation was limited to the ﬁrst 24 h postoperatively. In our
study, we showed signiﬁcant decrease in opioid consumption in
the PMDI group in the ﬁrst four hours after surgery and the trend
continued to POD 1, although the difference was not statistically
different at POD1, POD2 and POD3 (Fig. 1). Our results are
consistent with the 111  62 min half-life of ropivacaine, and the
thirty-minute maximum circulating level.20,21 However there was
less opioid consumption in the PMDI group. Similarly Joo et al.22
found no differences in patient pain, satisfaction or range of motion
between the PMDI and placebo groups at 12, 24, and 36 h after
surgery and on the 2nd and 14th day after surgery, though both
were without CFNB.
Although the VAS pain score was not signiﬁcantly different, less
opioid consumption with an equivalent pain score can be
interpreted as better pain relief. The most similar trial is a
crossover study for staged bilateral TKA in 16 patients.14 The

Fig. 3. Mean maximal knee ﬂexion range of motion (ROM) in degrees of control and
experimental groups on POD2 and POD3, during active and assisted active (PT
assisted) knee mobilization. Bar graph depicts mean values with whiskers
representing standard error values. No signiﬁcant difference between the control
and the experimental groups for all conditions on either POD2 or POD3.
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Table 3
Opioid side effect proﬁle of each group at different time intervals.
Control (n = 21)
4h

POD1

POD2

Experimental (n = 23)
POD3

Any SE

0
N/V
0
0
0
0
0
0
0
Dw
0
0
0
0
0
0
0
0
0
0
0

N/Dz
N/V
Dz
0
0
Dw
Dz
0
N
Dw
0
0
Dz
0
0
0
V
0
0
0
0

Dz
N/V/Dz
Dz
0
0
0
Dw
0
0
Dw
0
0
0
0
0
0
0
0
0
0
0

Dz
Dz
0
0
0
0
0
0
0
0
0
0
0
0
0
P
0
0
0
0
0

1
1
1
0
0
1
1
0
1
1
0
0
1
0
0
1
1
0
0
0
0

9.52%

42.86%

23.81%

14.28%

47.62%

4h

POD1

POD2

POD3

Any SE

0
Cf
0
0
0
0
0
0
0
0
0
0
0
0
0
N
0
0
0
0
0
0
0
8.70%

0
Cf
N/V/Dz
P/Dz
Dz
0
Dz
0
Dz
0
0
0
0
0
0
0
N
0
0
0
0
0
N
34.78%

N
Cf
N/V/Dz
N/Dz
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Dz
0
0
0
0
21.74%

0
Dz
0
0
0
0
0
0
0
0
0
0
0
C
0
0
0
0
0
0
0
0
0
8.70%

1
1
1
1
1
0
1
0
1
0
0
0
0
1
0
1
1
0
1
0
0
0
1
52.17%

Table shows the percentages of control and experimental group subjects experiencing opioid side effects (SE) at each time interval: 4 h, postoperative days (POD) 1, 2 and 3,
and total of any SE per group. There were no signiﬁcant differences between the groups at 4 h even though a signiﬁcant difference in opioid consumption was seen. Opioid side
effects: (C) constipation; (Cf) confusion; (Dz) dizziness; (Dw) drowsiness; (N) nausea; (P) pruritus; (V) vomiting.

authors used a single shot PMDI and saline CFNB compared to the
contralateral receiving saline periarticular injection and CFNB. In
contrast to our study, they found no signiﬁcant difference in
patient controlled opioid use or pain in the ﬁrst 72 h. Their study is
limited by the lack of a four-hour time point and a placebo CFNB
excluding the possible synergistic effect of the PMDI with CFNB.
Interestingly, we actually found signiﬁcant increases in the mean
pain scores in the PMDI group on POD two and three. We postulate
that our patients may have had a rebound effect from more
vigorous rehabilitation activity allowed by better analgesia during
the ﬁrst 24 h, A similar pattern was seen by Yuenyongviwat et al.,23
where the VAS pain score was higher, but not signiﬁcantly, in the
PA injection treatment group from 48 h to 96 h post-surgery. We
found a greater difference in average ROM values between active
and active assisted knee mobilization on POD two in the PMDI
group (Fig. 3). This reﬂects more pain in the PDMI group limiting
the patient’s ability to actively reach their passive potential. Again
this can be attributed to the rebound pain experienced from more
vigorous rehab on POD one.
The rebound increase in pain observed in our study on POD2
and POD3 indicates that a more robust pain control protocol is
needed during these times, especially as the effect of the PMDI
medications wears off. With the trend towards a multimodal
protocol that avoids parenteral narcotics, this would mean
endorsing a protocol with more preemptive pain medications or
changing the pro re nata (PRN) regimen to more of a standing
regimen. Currently our patients receive a standing long acting oral
narcotics with short acting narcotics and NSAIDs for break through
pain. Though this would increase our opioid consumption on POD
two and three, it may potentially give the beneﬁt of less pain, more
effective physical therapy with better ROM before discharge and
shorter length of stay. Another option could be the addition of a
liposomal bupivacaine periarticular injection to theoretically
decrease pain through POD 2-3, but more studies are needed to
validate this assumption in a consistent manner.24–26Although

there were no ‘patient falls’ in our study, adductor canal blocks are
another option that can potentially limit the undesirable quadriceps weakness seen in FNB with pain relief by targeting mostly
sensory nerves.27,28
We did not see any signiﬁcant differences in the side effect
proﬁles or patient satisfaction scores between the two groups. The
incidence of opioid-related side effects between groups was the
same even during the ﬁrst 4 h. post-operative when the difference
in morphine consumption was signiﬁcant, possibly due to shorter
sample size and low incidence of side effects.
5. Conclusion
The addition of a PMDI injection to our multimodal acute pain
treatment regimen for patients undergoing TKA leads to a decrease
in opioid consumption within the ﬁrst four hours after surgery, but
does not show a difference in the overall total consumption within
the ﬁrst three days postoperatively. However, the PMDI seems to
lead to higher pain scores on the second and third day after surgery
possibly attributed to a rebound effect. This observation provides
insight and an opportunity for better pain control with other
medications during this rebound period. This is important as the
patients may start feeling better and conﬁdent during the ﬁrst
postoperative day, and any further increase in pain may impact
them negatively both mentally and physically. Moreover, this
ﬁnding can also be a part of preoperative education so that the
patients and caregivers are not taken by surprise. The PMDI
injection has no signiﬁcant effect on levels of opioid side-effects or
patient satisfaction. This importance of this topic and lack of
consensus in TJA literature is evident by the number of
comparative randomized controlled trials that continue to emerge
regarding the combinations of periarticular PMDI, continuous or
single-shot FNB, continuous or single adductor canal blocks,
continuous postoperative, intraarticular infusions, and bupivacaine liposomal suspension.29
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